The Biologics License Application for CT-P47 was based on Phase III data comparing CT-P47 to the reference product ACTEMRA® (tocilizumab) JERSEY CITY, N.J., Jan. 28, 2024 /PRNewswire/ — Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.